pre 084 has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 2 studies
Studies (pre 084) | Trials (pre 084) | Recent Studies (post-2010) (pre 084) | Studies (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) | Trials (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) | Recent Studies (post-2010) (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) |
---|---|---|---|---|---|
116 | 0 | 73 | 3,859 | 8 | 1,052 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Chen, L; Hong, J; Sha, S; Wang, C; Yin, J; Zhou, L | 1 |
Cao, T; Guo, CH; Waddington, JL; Zhen, XC; Zheng, LT | 1 |
2 other study(ies) available for pre 084 and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Article | Year |
---|---|
Sigma-1 receptor deficiency reduces MPTP-induced parkinsonism and death of dopaminergic neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anisoles; Astrocytes; Cell Death; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Gene Expression Regulation; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microglia; Morpholines; Neuroprotective Agents; Parkinson Disease, Secondary; Pars Compacta; Phenols; Phosphorylation; Piperidines; Propylamines; Psychomotor Performance; Receptors, N-Methyl-D-Aspartate; Receptors, sigma; Sigma-1 Receptor; Signal Transduction; Vesicular Monoamine Transport Proteins | 2015 |
Development and characterization of an inducible Dicer conditional knockout mouse model of Parkinson's disease: validation of the antiparkinsonian effects of a sigma-1 receptor agonist and dihydromyricetin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; DEAD-box RNA Helicases; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Flavonols; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Morpholines; Oxidopamine; Parkinson Disease; Receptors, sigma; Ribonuclease III; Sigma-1 Receptor; Tamoxifen | 2020 |